We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comparison of Seroquel vs. Risperidone in Schizophrenia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00034905
First Posted: May 3, 2002
Last Update Posted: January 4, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The purpose of this study is to show equal efficacy of both quetiapine and risperidone in subjects treated with study medication for up to 8 weeks.

Condition Intervention Phase
Schizophrenia Drug: quetiapine fumarate vs risperidone Phase 4

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Study Start Date: July 2001
Study Completion Date: September 2002
Primary Completion Date: September 2002 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Male / Female, 18-65 years old
  • Schizophrenia (as per DSM IV)

Exclusion Criteria

  • Concurrent use of psychotropic medication
  • Does not fulfill moderately ill on CGI
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00034905


  Hide Study Locations
Locations
United States, Alabama
Birmingham, Alabama, United States
United States, Arizona
Phoenix, Arizona, United States
United States, California
Anaheim, California, United States
Cerritos, California, United States
Chula Vista, California, United States
Glendale, California, United States
Hawthorne, California, United States
Long Beach, California, United States
San Diego, California, United States
Santa Ana, California, United States
Torrance, California, United States
United States, Connecticut
Farmington, Connecticut, United States
New Haven, Connecticut, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Miami Beach, Florida, United States
Miami, Florida, United States
North Miami, Florida, United States
Winter Park, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Illinois
Hoffman Estates, Illinois, United States
United States, Kansas
Prairie Village, Kansas, United States
Wichita, Kansas, United States
United States, Louisiana
New Orleans, Louisiana, United States
Shreveport, Louisiana, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
Worcester, Massachusetts, United States
United States, Michigan
Ann Arbor, Michigan, United States
New Baltimore, Michigan, United States
United States, Missouri
Kansas City, Missouri, United States
St. Louis, Missouri, United States
United States, Nevada
Reno, Nevada, United States
United States, New Jersey
Clementon, New Jersey, United States
Lyons, New Jersey, United States
Summit, New Jersey, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
Bronx, New York, United States
Holliswood, New York, United States
Montrose, New York, United States
New York, New York, United States
Oceanside, New York, United States
White Plains, New York, United States
United States, North Carolina
Butner, North Carolina, United States
United States, Ohio
Beachwood, Ohio, United States
Chagrin Falls, Ohio, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Media, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
United States, Tennessee
Memphis, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
Austin, Texas, United States
Houston, Texas, United States
Terrell, Texas, United States
Waco, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Virginia
Falls Church, Virginia, United States
Richmond, Virginia, United States
Virginia Beach, Virginia, United States
United States, Washington
Kirkland, Washington, United States
Tacoma, Washington, United States
Vancouver, Washington, United States
United States, Wisconsin
West Allis, Wisconsin, United States
Sponsors and Collaborators
AstraZeneca
  More Information

ClinicalTrials.gov Identifier: NCT00034905     History of Changes
Other Study ID Numbers: 5077US/0043
First Submitted: May 2, 2002
First Posted: May 3, 2002
Last Update Posted: January 4, 2013
Last Verified: January 2013

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Risperidone
Quetiapine Fumarate
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents